PetVivo Holdings, Inc. reported fiscal 2026 revenue of $1.14M and a net loss of $10.47M, with diluted EPS of ($0.37), according to its 10-K filing. Revenue was essentially flat year‑over‑year while the company widened its net loss compared with fiscal 2025.
Financial Highlights
- Revenue was $1.14M for FY 2026, compared with $1.13M in FY 2025; YoY change 0.8%.
- Net income (loss) was a loss of $10.47M for FY 2026, compared with a loss of $8.40M in FY 2025 (worse YoY).
- Diluted earnings per share was ($0.37) for FY 2026, versus ($0.41) for FY 2025 (improved EPS loss YoY).
Business Highlights
- Revenue growth was driven by expanded product sales, with total revenue rising slightly to $1.142M from $1.133M in the prior year.
- The company saw a channel shift toward increased sales via distributors (including Vedco and Clipper) and direct veterinary clinic sales; PrecisePRP sales were added under a VetStem license.
- Commercialization of Spryng® and launch support for PrecisePRP supported higher sales and prompted increased sales and marketing investment.
- Inventory increased to $538K as finished‑goods levels were scaled to support commercialization activities.
- Management noted a limited near‑term cash runway and plans for additional capital raises to support continued commercialization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.